Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide.
about
A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humansT cell avidity and tumor recognition: implications and therapeutic strategies.Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic PeptidesAmino Acid Similarity Accounts for T Cell Cross-Reactivity and for “Holes” in the T Cell RepertoirePrevention of Cytotoxic T Cell Escape Using a Heteroclitic Subdominant Viral T Cell DeterminantExpressing Redundancy among Linear-Epitope Sequence Data Based on Residue-Level Physicochemical Similarity in the Context of Antigenic Cross-Reaction.Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccinesQuantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries.A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease.An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses.Thermostable direct hemolysin downregulates human colon carcinoma cell proliferation with the involvement of E-cadherin, and β-catenin/Tcf-4 signaling.HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation.Clinical implication of HLA class I expression in breast cancerHuman heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines.The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen.Strategies for designing and optimizing new generation vaccines.Cancer vaccines: progress reveals new complexities.Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.Optimizing vaccine design for cellular processing, MHC binding and TCR recognition.Identification of protective Lassa virus epitopes that are restricted by HLA-A2.Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes.Design of multi-epitope, analogue-based cancer vaccines.HLA-A2-restricted protection against lethal lymphocytic choriomeningitis.The CD8+ T-cell response to lymphocytic choriomeningitis virus involves the L antigen: uncovering new tricks for an old virusExtended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancerMultiple costimulatory modalities enhance CTL avidity.Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaEscape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitopeTranslational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve.Mobilizing the low-avidity T cell repertoire to kill tumors.Accurate structure prediction of peptide-MHC complexes for identifying highly immunogenic antigens.Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma.Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humansNovel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patientsAberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.Peptide-based vaccines for cancer: realizing their potential.
P2860
Q24611383-F3B3D865-C4C0-4B6A-89A1-741D9C084D56Q24815775-3FCA7DA4-F4E9-476E-AEAD-40B1CF96A7AAQ26800123-C0910B77-EE6B-4123-9A1C-127F970FC1E7Q27485470-9933739F-8851-47E4-9B53-FEC8003FCE95Q27652640-AA369726-4000-4343-8607-0D1BC3EE60FCQ31106414-8C4C45FE-0C8A-47A4-B146-E6F5605491C5Q33255244-F4DFBFE6-6A8C-41D7-AC92-26B6192F4281Q33316579-26F7799A-ECE0-4C8F-88B5-C28DA3A4D251Q33519507-1741DDA8-152C-423B-9DDA-69CE44005C49Q33830488-42ADD763-E654-440C-90D1-46217CBB1FA0Q33916259-281BBDF6-A640-4B80-A18C-432B70C7D096Q34048199-F9545A07-0B29-4003-B3FA-ECD816A648B4Q34052449-FDCDB84F-D960-4D75-A74F-8DE91A421C37Q34052565-8873BCE8-26EF-4227-84C3-1229B7B07315Q34155839-9F3C45CF-AB29-4A6B-AA80-49F718A049ABQ34380820-1EE9C876-2C59-41F7-B3CA-2C9C4D9BF5C9Q34482074-7FC5D13D-3159-4E66-A563-061E65994A0FQ34572198-C335BF1E-2078-4F6E-A8C7-3BA5BDFF6FCEQ34774541-40F3D8B5-8E5E-4B56-ADFC-6DAB17DB0FB7Q35005935-F5A11BAB-7115-4CA6-8C9E-65A6270C7C35Q35005969-C33617E3-41C1-40F8-B1AE-AC720D312ACCQ35024149-F78863A8-8033-4871-A0D5-F56DA95EA08DQ35193438-508F3952-409E-423A-B8B3-DABC0AFD5281Q35207535-B9EB9E5D-ABCA-42DF-9514-AB93E5301C52Q35784663-883DECE4-DCB3-4890-ACB0-FE126891ECC1Q35857498-5EB1AF10-98A9-4F5C-A28F-B7B40482FE16Q35864700-8AD84ACF-9BB9-47E4-A7EF-CB2ECB895674Q35901490-D437B1C9-0B5C-49A6-9FC7-C79B8CB34AD8Q35989451-C393EF6F-B415-4570-8E36-73E6527BA89FQ36150417-896716B6-AF29-4E31-BBA8-487FAB22CC15Q36627951-644C6349-273F-41ED-9CF1-C4B282187414Q36793112-EF699AAF-71F7-414F-A75B-651B79BD6739Q36871818-450E9F54-9538-40EB-9B19-C853A24BD3CCQ36891310-FFEB7154-39C4-418D-9EF7-96D7BBB398A4Q36941362-3A376568-548A-4B59-8D12-2E992A2BEF9DQ36965049-4CF80020-540C-4EB1-84FD-30DA3086C1D4Q36994720-6561B998-3C30-4511-9F46-F504517BB6A5Q37068071-2275C51A-52EA-44DE-9626-798D61103117Q37290676-6896FCA3-DFCD-4E70-B152-1B041AAE1CCFQ37340462-626905F4-3FA5-4A2D-8EC2-0108B1AD60EE
P2860
Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Structural features of peptide ...... ogenic than wild-type peptide.
@ast
Structural features of peptide ...... ogenic than wild-type peptide.
@en
type
label
Structural features of peptide ...... ogenic than wild-type peptide.
@ast
Structural features of peptide ...... ogenic than wild-type peptide.
@en
prefLabel
Structural features of peptide ...... ogenic than wild-type peptide.
@ast
Structural features of peptide ...... ogenic than wild-type peptide.
@en
P2093
P2860
P356
P1476
Structural features of peptide ...... ogenic than wild-type peptide.
@en
P2093
G Y Ishioka
S Southwood
P2860
P304
P356
10.1084/JEM.194.6.833
P407
P577
2001-09-01T00:00:00Z